Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Related Citations for PubMed (Select 23825648)

1.

Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.

Krejsa CM, Holly RD, Heipel M, Bannink KM, Johnson R, Roque R, Heffernan J, Hill J, Chin L, Wagener F, Shiota F, Henderson K, Sivakumar PV, Ren HP, Barahmand-Pour F, Foster D, Clegg C, Kindsvogel W, Ponce R, Hughes SD, Waggie K.

PLoS One. 2013 Jun 25;8(6):e67256. doi: 10.1371/journal.pone.0067256. Print 2013.

2.

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.

Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.

J Immunother. 2007 Jan;30(1):64-74.

PMID:
17198084
3.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.

Blood. 2011 Oct 13;118(15):4159-68. doi: 10.1182/blood-2011-04-351932. Epub 2011 Jul 27.

4.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
5.

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.

J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1.

PMID:
19483647
6.

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.

Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.

PMID:
20056126
7.

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M.

Haematologica. 2003 Sep;88(9):1002-12.

8.

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.

Kobayashi H, Matsunaga Y, Uchiyama Y, Nagura K, Komatsu Y.

Cancer Med. 2013 Apr;2(2):130-43. doi: 10.1002/cam4.60. Epub 2013 Feb 20.

9.

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS.

Br J Haematol. 2012 Feb;156(4):490-8. doi: 10.1111/j.1365-2141.2011.08966.x. Epub 2011 Dec 9.

PMID:
22150234
10.

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.

Nickerson-Nutter C, Tchistiakova L, Seth NP, Kasaian M, Sibley B, Olland S, Zollner R, Brady WA, Mohler KM, Baum P, Wahl A, Herber D, Vugmeyster Y, Wensel D, Wolfman NM, Gill D, Collins M, Dunussi-Joannopoulos K.

Rheumatology (Oxford). 2011 Jun;50(6):1033-44. doi: 10.1093/rheumatology/keq423. Epub 2011 Jan 21.

11.

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillasson M, Loisel S, Béchard D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quéméner A.

MAbs. 2014 Jul-Aug;6(4):1026-37.

PMID:
25072059
12.

Effect of alemtuzumab on neoplastic B cells.

Golay J, Manganini M, Rambaldi A, Introna M.

Haematologica. 2004 Dec;89(12):1476-83.

13.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

14.

Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.

Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A, Touitou V, Daussy C, Naud MC, Fridman WH, Sautès-Fridman C, Urbain R, Fisson S.

Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3657-65. doi: 10.1167/iovs.12-10316.

15.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
16.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P.

Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.

17.

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.

Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, Jallal B, Herbst R.

Br J Haematol. 2011 Nov;155(4):426-37. doi: 10.1111/j.1365-2141.2011.08857.x. Epub 2011 Sep 9.

PMID:
21902688
18.

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D.

Invest New Drugs. 2010 Oct;28(5):561-74. doi: 10.1007/s10637-009-9291-z. Epub 2009 Jul 21.

PMID:
19626278
19.

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab J.

PLoS Med. 2008 Mar 25;5(3):e64. doi: 10.1371/journal.pmed.0050064.

20.

[Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].

Zhang WX, Guo J, Lin BH, Meng SN, Wang XP, Xie Y, Zheng W, Zhang YT, Zhu J.

Zhonghua Xue Ye Xue Za Zhi. 2007 Jan;28(1):41-4. Chinese.

PMID:
17649726
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk